Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

Peter A. Kaufman; Hans Wildiers; Gilles Freyer; Margaret Kemeny; Anthony Gonçalves; Guy Jerusalem; Alison Stopeck; Nandagopal Vrindavanam; Florence Dalenc; Nuwan Nanayakkara; Benjamin Wu; Cheryl A. Pickett

doi:10.1016/j.clbc.2018.09.012

Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

Peter A. Kaufman, Hans Wildiers, Gilles Freyer, Margaret Kemeny, Anthony Gonçalves, Guy Jerusalem, Alison Stopeck, Nandagopal Vrindavanam, Florence Dalenc, Nuwan Nanayakkara, Benjamin Wu, Cheryl A. Pickett

Cancer Center

Research output: Contribution to journal › Article

2 Scopus citations

Abstract

Given the potential interactions between human epidermal growth factor receptor 2 (HER2) signaling and angiogenesis, we investigated the angiopoietin (Ang) 1/Ang2 inhibitor trebananib plus trastuzumab and paclitaxel in HER2-positive breast cancer. Forty women received trebananib (10 or 30 mg/kg) plus trastuzumab and paclitaxel. The combination demonstrated acceptable toxicity and antitumor response in HER2-positive locally recurrent/metastatic breast cancer.

Original language	English (US)
Pages (from-to)	47-57
Number of pages	11
Journal	Clinical Breast Cancer
Volume	19
Issue number	1
DOIs	https://doi.org/10.1016/j.clbc.2018.09.012
State	Published - Feb 2019

Keywords

AMG 386
Angiogenesis
Angiopoietin
HER2 positive

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/j.clbc.2018.09.012

Fingerprint Dive into the research topics of 'Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer'. Together they form a unique fingerprint.

Cite this

Kaufman, P. A., Wildiers, H., Freyer, G., Kemeny, M., Gonçalves, A., Jerusalem, G., Stopeck, A., Vrindavanam, N., Dalenc, F., Nanayakkara, N., Wu, B., & Pickett, C. A. (2019). Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer. Clinical Breast Cancer, 19(1), 47-57. https://doi.org/10.1016/j.clbc.2018.09.012

Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer. / Kaufman, Peter A.; Wildiers, Hans; Freyer, Gilles; Kemeny, Margaret; Gonçalves, Anthony; Jerusalem, Guy; Stopeck, Alison; Vrindavanam, Nandagopal; Dalenc, Florence; Nanayakkara, Nuwan; Wu, Benjamin; Pickett, Cheryl A.

In: Clinical Breast Cancer, Vol. 19, No. 1, 02.2019, p. 47-57.

Research output: Contribution to journal › Article

Kaufman, PA, Wildiers, H, Freyer, G, Kemeny, M, Gonçalves, A, Jerusalem, G, Stopeck, A, Vrindavanam, N, Dalenc, F, Nanayakkara, N, Wu, B & Pickett, CA 2019, 'Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer', Clinical Breast Cancer, vol. 19, no. 1, pp. 47-57. https://doi.org/10.1016/j.clbc.2018.09.012

Kaufman, Peter A. ; Wildiers, Hans ; Freyer, Gilles ; Kemeny, Margaret ; Gonçalves, Anthony ; Jerusalem, Guy ; Stopeck, Alison ; Vrindavanam, Nandagopal ; Dalenc, Florence ; Nanayakkara, Nuwan ; Wu, Benjamin ; Pickett, Cheryl A. / Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer. In: Clinical Breast Cancer. 2019 ; Vol. 19, No. 1. pp. 47-57.

@article{63ebd5b98fa0477bb293094f3327cccc,

title = "Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer",

abstract = "Given the potential interactions between human epidermal growth factor receptor 2 (HER2) signaling and angiogenesis, we investigated the angiopoietin (Ang) 1/Ang2 inhibitor trebananib plus trastuzumab and paclitaxel in HER2-positive breast cancer. Forty women received trebananib (10 or 30 mg/kg) plus trastuzumab and paclitaxel. The combination demonstrated acceptable toxicity and antitumor response in HER2-positive locally recurrent/metastatic breast cancer.",

keywords = "AMG 386, Angiogenesis, Angiopoietin, HER2 positive",

author = "Kaufman, {Peter A.} and Hans Wildiers and Gilles Freyer and Margaret Kemeny and Anthony Gon{\c c}alves and Guy Jerusalem and Alison Stopeck and Nandagopal Vrindavanam and Florence Dalenc and Nuwan Nanayakkara and Benjamin Wu and Pickett, {Cheryl A.}",

year = "2019",

month = feb,

doi = "10.1016/j.clbc.2018.09.012",

language = "English (US)",

volume = "19",

pages = "47--57",

journal = "Clinical Breast Cancer",

issn = "1526-8209",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

AU - Kaufman, Peter A.

AU - Wildiers, Hans

AU - Freyer, Gilles

AU - Kemeny, Margaret

AU - Gonçalves, Anthony

AU - Jerusalem, Guy

AU - Stopeck, Alison

AU - Vrindavanam, Nandagopal

AU - Dalenc, Florence

AU - Nanayakkara, Nuwan

AU - Wu, Benjamin

AU - Pickett, Cheryl A.

PY - 2019/2

Y1 - 2019/2

N2 - Given the potential interactions between human epidermal growth factor receptor 2 (HER2) signaling and angiogenesis, we investigated the angiopoietin (Ang) 1/Ang2 inhibitor trebananib plus trastuzumab and paclitaxel in HER2-positive breast cancer. Forty women received trebananib (10 or 30 mg/kg) plus trastuzumab and paclitaxel. The combination demonstrated acceptable toxicity and antitumor response in HER2-positive locally recurrent/metastatic breast cancer.

AB - Given the potential interactions between human epidermal growth factor receptor 2 (HER2) signaling and angiogenesis, we investigated the angiopoietin (Ang) 1/Ang2 inhibitor trebananib plus trastuzumab and paclitaxel in HER2-positive breast cancer. Forty women received trebananib (10 or 30 mg/kg) plus trastuzumab and paclitaxel. The combination demonstrated acceptable toxicity and antitumor response in HER2-positive locally recurrent/metastatic breast cancer.

KW - AMG 386

KW - Angiogenesis

KW - Angiopoietin

KW - HER2 positive

UR - http://www.scopus.com/inward/record.url?scp=85056336575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056336575&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2018.09.012

DO - 10.1016/j.clbc.2018.09.012

M3 - Article

C2 - 30420181

AN - SCOPUS:85056336575

VL - 19

SP - 47

EP - 57

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 1

ER -